CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED.Regeneron Pharmaceuticals, Inc. • February 8th, 2021 • Pharmaceutical preparations
In accordance with the terms and conditions of the referenced MCDC Base Agreement, Modification No. 02 hereby amends the Project Agreement No. 01 as follows:
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT, MARKED BY BRACKETS, WERE OMITTED BECAUSE THOSE PORTIONS ARE NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL TO THE COMPANY IF PUBLICLY DISCLOSED.Certain • February 8th, 2021 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations
This Project Agreement is awarded under the authority of MCDC Base Agreement No. 2020-504, and herein incorporates all the terms and conditions thereof, as such terms and conditions are modified by the terms of the Statement Of Work attached hereto as Exhibit A (the “Statement of Work” or “SOW”). The parties agree that, to the extent any terms or conditions of the Statement of Work conflict with the terms and conditions of MCDC Base Agreement No. 2020-504, the terms and conditions of the Statement of Work shall apply and take precedence.
Attention: Subject: Modification No. 01 to Project Agreement No. 01; MCDC2008-005 Reference: MCDC Base Agreement No. 2020-504Regeneron Pharmaceuticals, Inc. • February 8th, 2021 • Pharmaceutical preparations
In accordance with the terms and conditions of the referenced MCDC Base Agreement, Modification No. 01 hereby amends the Project Agreement No. 01 as follows:
